AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 464673 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose with an amino acid solution containing 35% BCAAs
Number of subjects: 35
Study 464673 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose with an amino acid solution containing 100% BCAAs
Number of subjects: 35
Study 464673 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose only
Number of subjects: 35
Study 31075393 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (dronabinol; 5-50 mg, dose individually tailored)
Number of subjects: 54
Study 31075393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to THC)
Number of subjects: 54
Study 27402452 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated low glucose insulin suspension system (intervention nights)
Number of subjects: 82
Study 27402452 — intervention group
Group type: COMPARATOR
Intervention: Control nights (system not activated)
Number of subjects: 82
Study 27402452 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of pump suspension
Number of subjects: 82
Study 25541530 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 1391
Study 25541530 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 1391
Study 25541530 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 1391
Study 25541530 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (in WOMB trial)
Number of subjects: 1391
Study 25541530 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective and emergency cesarean section
Number of subjects: 1391
Study 25541530 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 1391
Study 25301831 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF >50%
Number of subjects: 752
Study 25301831 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF 36%-50%
Number of subjects: 752
Study 25301831 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with all 6 factors associated with LVEF normalization
Number of subjects: 752
Study 22559906 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNP-directed intervention including discussions of hospice benefits and advanced directives (Five Wishes document)
Number of subjects: 26
Study 22559906 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 26
Study 19770386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m(2) twice weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm A)
Number of subjects: 81
Study 19770386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m(2) weekly plus rituximab 375 mg/m(2) weekly for 4 weeks (arm B)
Number of subjects: 81
Study 19770386 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as single-agent rituximab in ongoing phase III study)
Number of subjects: 81
Study 17803818 — intervention group
Group type: EXPERIMENTAL
Intervention: ProAlgaZyme (4 fl oz daily)
Number of subjects: 60
Study 17803818 — intervention group
Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 60
Study 15249319 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g/day (n = 405)
Number of subjects: 779
Study 15249319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 374)
Number of subjects: 779
Study 15249319 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (n = 63) in chronic mechanical knee pain subgroup
Number of subjects: 779
Study 15249319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 60) in chronic mechanical knee pain subgroup
Number of subjects: 779
Study 12212663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg clonidine
Number of subjects: 10
Study 12212663 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg yohimbine
Number of subjects: 10
Study 12212663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10325993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hs + Ad group (Hartmann's solution containing 0.5 ml of 1:1000 adrenaline per 500 ml)
Number of subjects: 10
Study 10325993 — intervention group
Group type: COMPARATOR
Intervention: Hs group (Hartmann's solution alone)
Number of subjects: 10
Study 10325993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hs + Ad group
Number of subjects: 10
Study 10325993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study 7704169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine
Number of subjects: 1278
Study 7704169 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype 1 vaccine
Number of subjects: 1278
Study 7704169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278
Study 2497131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile s.c. FSH
Number of subjects: 31
Study 2497131 — intervention group
Group type: COMPARATOR
Intervention: i.m. FSH
Number of subjects: 31
Study 504973 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (s.c.) injected twice a day
Number of subjects: 48
Study 504973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin (i.v.) given by continuous perfusion
Number of subjects: 48
Study 504973 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 48
Study 30734016 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy administration
Number of subjects: 15057
Study 30734016 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric resections
Number of subjects: 15057
Study 30734016 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative survival rate
Number of subjects: 15057
Study 28460479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 8405
Study 28460479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 8405
Study 28460479 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 8405
Study 26062880 — intervention group
Group type: COMPARATOR
Intervention: Triple treatment (lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide)
Number of subjects: 250
Study 26062880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual treatment (lopinavir-ritonavir plus lamivudine)
Number of subjects: 250
Study 26062880 — intervention group
Group type: COMPARATOR
Intervention: Triple treatment
Number of subjects: 250
Study 26062880 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual treatment
Number of subjects: 250
Study 23385647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg/day
Number of subjects: 31
Study 23385647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21248328 — intervention group
Group type: COMPARATOR
Intervention: C:SH diet fed ad libitum for 28 d
Number of subjects: 672
Study 21248328 — intervention group
Group type: EXPERIMENTAL
Intervention: C:WM:20DDGS diet
Number of subjects: 672
Study 21248328 — intervention group
Group type: EXPERIMENTAL
Intervention: C:SH:10DDGS diet
Number of subjects: 672
Study 21248328 — intervention group
Group type: EXPERIMENTAL
Intervention: Limit feeding diets containing DDGS at levels of 65 or 55 g/hen per day during the molt period
Number of subjects: 672
Study 21248328 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 672
Study 19837435 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin plus tamsulosin
Number of subjects: 398
Study 19837435 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus tamsulosin
Number of subjects: 398
Study 17085151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 160 mg once daily for 8 weeks
Number of subjects: 125
Study 17085151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 17125603 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV, DAIDING)
Number of subjects: 209
Study 17125603 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LAM)
Number of subjects: 209
Study 14512778 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) - Internet-based program for 6 months
Number of subjects: 104
Study 14512778 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 104
Study 11776118 — intervention group
Group type: EXPERIMENTAL
Intervention: Etimicin
Number of subjects: 65
Study 11776118 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 65
Study 8653330 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 108
Study 8653330 — intervention group
Group type: COMPARATOR
Intervention: Cervical lymphadenectomy
Number of subjects: 108
Study 8653330 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 108
Study 2004322 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (external irradiation to a dose of 5000 cGy in 5 weeks)
Number of subjects: 172
Study 2004322 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 172
Study 6674819 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole (Heminevrin)
Number of subjects: 40
Study 6674819 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (Librium)
Number of subjects: 40
Study 29739753 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 342
Study 29739753 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 342
Study 27916699 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training program (4 months), including pedometer, elastic resistance bands, DVD, training manual, calendars, log-book, video coaching calls, newsletters
Number of subjects: 57
Study 27916699 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 57
Study 26077795 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative management (PPCM) model
Number of subjects: 539
Study 26077795 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 539
Study 23104435 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model framework for data synthesis
Number of subjects: 0
Study 23104435 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach to estimation
Number of subjects: 0
Study 23104435 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of deviance information criterion
Number of subjects: 0
Study 20969601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days
Number of subjects: 11
Study 20969601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 0.5 mg twice daily
Number of subjects: 11
Study 20969601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 200 mg twice daily for 7 days with finasteride 1.0 mg twice daily
Number of subjects: 11
Study 19004202 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight-noon ebb-flow method of selecting acupoints (MNEFMSA)
Number of subjects: 90
Study 19004202 — intervention group
Group type: COMPARATOR
Intervention: Affected-channel group (acupuncture at points along the affected channel)
Number of subjects: 90
Study 19004202 — intervention group
Group type: COMPARATOR
Intervention: Drug group (routine medication)
Number of subjects: 90
Study 19004202 — intervention group
Group type: EXPERIMENTAL
Intervention: MNEFMSA group
Number of subjects: 90
Study 19004202 — intervention group
Group type: COMPARATOR
Intervention: All groups (including MNEFMSA, affected-channel, and drug)
Number of subjects: 90
Study 16915024 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training (MODE)
Number of subjects: 39
Study 16915024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance training and endurance training (COMBO)
Number of subjects: 39
Study 16915024 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (CONTROL)
Number of subjects: 39
Study 15129702 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal standardized uptake values (SUV) in the mediastinal metastasis group (4.9 +/- 1.8)
Number of subjects: 70
Study 15129702 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal SUV cut-off value of 3.4
Number of subjects: 70
Study 15129702 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal SUV
Number of subjects: 70
Study 15129702 — intervention group
Group type: COMPARATOR
Intervention: Maximal SUV in normal subjects
Number of subjects: 70
Study 11763952 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil‐containing (EOC) dentifrice
Number of subjects: 12
Study 11763952 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 12
Study 9314461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate alone
Number of subjects: 81
Study 9314461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate
Number of subjects: 81
Study 9314461 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate plus allopurinol
Number of subjects: 81
Study 9314461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate alone and sodium stibogluconate plus allopurinol
Number of subjects: 81
Study 8269208 — intervention group
Group type: EXPERIMENTAL
Intervention: m7E3 Fab (0.15 to 0.35 mg/kg)
Number of subjects: 23
Study 8269208 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg orally per day)
Number of subjects: 23
Study 3518384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (mean titrated dose 96 +/- 9 mg, mean treatment dose 63 +/- 21 mg administered 3 times daily)
Number of subjects: 17
Study 3518384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30200078 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (ETN50)
Number of subjects: 64
Study 30200078 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 64
Study 27441577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic (cefazolin 2 g 30 min before surgery with repetition at 1 g every 3 h during surgery)
Number of subjects: 150
Study 27441577 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (Control)
Number of subjects: 150
Study 21799164 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of carotid luminal narrowing over 1 year
Number of subjects: 1469
Study 21799164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral neurological events
Number of subjects: 1469
Study 21799164 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and previous contralateral symptoms
Number of subjects: 1469
Study 21799164 — intervention group
Group type: EXPERIMENTAL
Intervention: High rates of progression
Number of subjects: 1469
Study 21799164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low progression rates or regression
Number of subjects: 1469
Study 23087488 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (typical antipsychotic medication)
Number of subjects: 0
Study 23087488 — intervention group
Group type: COMPARATOR
Intervention: Newer atypical antipsychotics
Number of subjects: 0
Study 20729148 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg per day)
Number of subjects: 199
Study 20729148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 18728923 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS063DP (Atopiclair), applied three times per day for up to 50 days
Number of subjects: 218
Study 15930018 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate (CC)
Number of subjects: 72
Study 12697116 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng injection
Number of subjects: 123
Study 12697116 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based chemotherapy without Shenqi Fuzheng injection
Number of subjects: 123
Study 10965085 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical BP control (BP <140/90 mm Hg)
Number of subjects: 100
Study 10965085 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM control (BP during daytime <132/85 mm Hg)
Number of subjects: 100
Study 10965085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both clinical and ABPM control
Number of subjects: 100
Study 10965085 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled patients
Number of subjects: 100
Study 9162613 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg day(‐1))
Number of subjects: 291
Study 9162613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 1996588 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 79
Study 1996588 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 79
Study 6504620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifiers (non-nutritive sucking)
Number of subjects: 144
Study 6504620 — intervention group
Group type: COMPARATOR
Intervention: No pacifiers (control)
Number of subjects: 144
Study 30093681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamibarotene (6 mg/m2 daily for 14 days every 3 months for 2 years)
Number of subjects: 269
Study 30093681 — intervention group
Group type: COMPARATOR
Intervention: All-trans retinoic acid (ATRA) (45 mg/m2 daily for 14 days every 3 months for 2 years)
Number of subjects: 269
Study 30093681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Number of subjects: 269
Study 30093681 — intervention group
Group type: COMPARATOR
Intervention: ATRA
Number of subjects: 269
Study 30093681 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival after randomization
Number of subjects: 269
Study 30093681 — intervention group
Group type: EXPERIMENTAL
Intervention: Late complications (secondary hematopoietic disorders, secondary malignancies, grade 3 or more late cardiac comorbidities)
Number of subjects: 269
Study 30347030 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐CRA plus monthly injections of intravitreal ranibizumab, 0.5 mg (combination group; n = 29)
Number of subjects: 58
Study 30347030 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab alone (sham procedure plus monthly injections of intravitreal ranibizumab, 0.5 mg; n = 29)
Number of subjects: 58
Study 27603152 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME program (enhanced occupational therapy discharge planning intervention with pre- and postdischarge home visits)
Number of subjects: 400
Study 27603152 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME program
Number of subjects: 400
Study 27603152 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care intervention with in-hospital consultation)
Number of subjects: 400
Study 25105874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Body Control Program (ABC), n = 60
Number of subjects: 184
Study 25105874 — intervention group
Group type: EXPERIMENTAL
Intervention: 4sigma telephone coaching (4S), n = 58
Number of subjects: 184
Study 25105874 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 62
Number of subjects: 184
Study 23272061 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell vaccination (TCV)
Number of subjects: 26
Study 23272061 — intervention group
Group type: COMPARATOR
Intervention: Sham injections (Control)
Number of subjects: 26
Study 20386343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral estrogen (1 mg) combined with drospirenone (2 mg) for 2 years
Number of subjects: 26
Study 20386343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19117517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 51
Study 15996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric cervical strength measured in chronic whiplash patients
Number of subjects: 97
Study 15996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion/extension strength ratio
Number of subjects: 97
Study 15996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of flexion/extension strength ratio with mean coefficient of variation
Number of subjects: 97
Study 12645863 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol treatment for 12 weeks
Number of subjects: 67
Study 12645863 — intervention group
Group type: COMPARATOR
Intervention: Fertile control group
Number of subjects: 67
Study 12645863 — intervention group
Group type: COMPARATOR
Intervention: Explained infertility group
Number of subjects: 67
Study 12645863 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexplained infertility patients
Number of subjects: 67
Study 10745187 — intervention group
Group type: EXPERIMENTAL
Intervention: Social problem solving measures (Problem Solving Inventory and Rusk Problem Solving Role Play Test)
Number of subjects: 34
Study 10745187 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional neuropsychological measures (WAIS‐R/II Comprehension subtest and Wisconsin Card Sorting Test)
Number of subjects: 34
Study 10745187 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 34
Study 8621010 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) 50 mg q.i.d.
Number of subjects: 19
Study 8621010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1447664 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 47
Study 1447664 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 47
Study 1447664 — intervention group
Group type: EXPERIMENTAL
Intervention: No therapy
Number of subjects: 47
Study 3905050 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 3905050 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 31812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Belapectin 2 mg/kg
Number of subjects: 162
Study 31812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Belapectin 8 mg/kg
Number of subjects: 162
Study 31812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Belapectin 2 mg/kg (subgroup without esophageal varices)
Number of subjects: 162
Study 31812510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162